27 October 2022

Shelf-life for Accrufer® extended to 48 months

Shield Therapeutics plc (LSE: STX), announces that US Food and Drug Administration (‘FDA’) has approved the extension of the expiration for Accrufer® (ferric maltol) from 36 months to 48 months.

Greg Madison, CEO of Shield Therapeutics, stated: “Over the past year, we have doubled the shelf-life or time to expiry for Accrufer® from 24 to 48 months. Not only does this confirm the stable and robust nature of the capsule formulation of Accrufer®, but also provides additional supply chain flexibility and simplifies global logistics as we continue to support our growing US business and our license partners across the globe.”

For further details click here

Back to News